What is the current stock price of Caris Life Sciences, Inc. (CAI)?

As of the latest market data, Caris Life Sciences, Inc. (CAI) is trading at $21.15. The stock has seen a gain of 3.68% today.

Does Caris Life Sciences, Inc. (CAI) pay a dividend?

Based on current data, Caris Life Sciences, Inc. does not have a confirmed active dividend policy.

What is the market cap of Caris Life Sciences, Inc.?

The current market capitalization of Caris Life Sciences, Inc. (CAI) is approximately unavailable.

CAI

Caris Life Sciences, Inc.·Healthcare

21.15

3.676%(+0.75)

Market Closed

21.45

1.418%(+0.30)

After Hours

Last Updated: — ET

52W L: $16.2852W H: $42.50

CAI NEWS

prnewswire.com

1d ago

Caris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer Center

IRVING, Texas, April 17, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the UCSF Helen Diller Family Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance® (POA). The Caris POA is a global network of leading cancer centers and research groups that collaborate to advance precision oncology and biomarker-driven research.

prnewswire.com

3d ago

Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients

Comprehensive molecular profiling paired with biomarker-driven trial matching provides cancer patients with a complete pathway from diagnosis to treatment across more than 600 locations nationwide IRVING, Texas, April 15, 2026 /PRNewswire/ -- Caris Life Sciences® , Inc. (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today highlighted the growing urgency of closing the geographic gap in cancer clinical trial access and the role its Right-In-Time (RIT) clinical trial solution plays in bringing biomarker-driven trials to community oncology practices nationwide. Research published in JCO Oncology Practice found that 70% of U.S. counties had no active cancer treatment trials, leaving nearly one in five Americans ages 55 and older without a local pathway to investigational therapies.

seekingalpha.com

5d ago

Caris Life Sciences: Post-IPO Pullback Creates A Long-Term Buy Opportunity

Caris Life Sciences' approach pairs molecular profiling, AI, and large clinico-genomic datasets to support oncology diagnostics, therapy selection, and R&D. Its core platforms are the MI Profile and Caris Assure. These contributed to CAI's strong 2025 revenue growth. CAI clearly benefited from higher reimbursements, better pricing, and rising test volumes in 2025.

prnewswire.com

Apr 8

Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients

Caris AI Insights are proprietary and only available to Caris Life Sciences customers IRVING, Texas, April 8, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the launch of a groundbreaking AI-driven molecular insight for a subset of mono-immunotherapy eligible non-small cell lung cancer (NSCLC) patients. The NSCLC immunotherapy (IO) treatment selection signature was developed to determine which patients benefit from the addition of chemotherapy versus those who are harmed by the addition of chemotherapy.

prnewswire.com

Apr 2

Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies

Ultra-deep Whole Genome and Transcriptome Sequencing provides a more complete workup for myeloid malignancies with clearer, faster diagnostic insight IRVING, Texas, April 2, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced the launch of Caris ChromoSeq™, a Whole Genome Sequencing (WGS) and Whole Transcriptome (WTS) assay designed to support the comprehensive clinical genomic evaluation of myeloid malignancies. The test is intended for use in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN), as well as in patients with suspected myeloid malignancies characterized by unexplained cytopenia persisting for more than four months, where other potential causes have been reasonably excluded.

prnewswire.com

Mar 31

Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect

Results demonstrate the superiority of Whole Genome Sequencing compared to methylation-based approaches IRVING, Texas, March 31, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the finalized Achieve 1 Study results. These results represent a major milestone in Caris' goal to detect cancer earlier, through the future launch of Caris Detect™, its multi-cancer early detection (MCED) test.

Company Profile

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.

Sector

Healthcare

Industry

Biotechnology

Employees

1,769

IPO Date

2025-06-18

Beta

1.33

Websitewww.carislifesciences.com↗